Clinical trial of telbivudine in the treatment of chronic hepatitis B in patients during the third trimester of pregnancy

Jiang XiuNong; Fan LingYan; Li DeZhou; Wan Jiong; Ye JingJing

Issue 2

Feb. 2013

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2013 > 29(2): 101-103

PDF( 1036 KB)

Clinical trial of telbivudine in the treatment of chronic hepatitis B in patients during the third trimester of pregnancy

Research funding:

Published Date: 2013-02-20

Abstract

Abstract

Objective To investigate the significance of telbivudine (LdT) in controlling hepatitis activity and blocking mother-to-infant transmission of hepatitis B virus (HBV) in women with chronic hepatitis B (CHB) during late pregnancy.Methods A total of 116 pregnant women were enrolled.Each was positive for hepatitis B surface antigen (HBsAg) , hepatitis B e-antigen (HBeAg) and hepatitis B core antibody (anti-HBc) .They all also had HBV DNA levels of ≥105 copies/ml and alanine amino transferase (ALT) levels of ≥2×ULN, with or without total bilirubin (TBil) increase.They were divided into two groups based upon their personal preference, the treatment group (n=65) and control group (n=51) .The patients in the treatment group were (28±2) weeks pregnant and received LdT 600 mg once daily in addition to liver-protecting and enzyme-reducing treatments, while the patients in the control group received only the standard liver-protecting and enzyme-reducing treatment.All infants delivered by the participants received both active and passive immunization after birth.The women in the two groups were compared in terms of the HBV DNA, ALT and TBIL levels before delivery and at 7 months after delivery;positive rates of HBsAg and hepatitis B surface antibody (anti-HBs) were compared in the infants in both groups at 7 months after birth.Furthermore, maternal and neonatal complications were observed.Results The levels of serum HBV DNA, ALT and TBIL in the treatment group were significantly lower than those in the control group before delivery and at 7 months after delivery (P<0.05) .At 7 months after birth, the infants in the treatment group had a significantly lower positive rate for HBsAg (1.5% vs.15.7%, P<0.05) and a significantly higher anti-HBs-positive rate (95.4% vs.78.4%, P<0.05) compared with those in the control group.Maternal and neonatal complications occurred significantly less frequently in the treatment group than in the control group.Conclusion LdT is effective in controlling hepatitis activity in pregnant women with CHB, as it rapidly decreases HBV DNA levels and reduces mother-to-infant transmission of HBV.Its use is therefore beneficial to both mothers and infants.
- telbivudine,
- hepatitis B,
- chronic,
- pregnancy

FullText(HTML)

References(10)

References

[1]Swat S, Manoj K.Pregnancy and chronic hepatitis B virus in-fection[J].Hepatol Res, 2010, 40 (1) :31-48.

[2] Hoofnagle JH, Doo E, Liang TJ, et al.Management of hep-atitis B:summary of a clinical researchworkshop[J].Hepa-tology, 2007, 45 (4) :1056-1075.

[3] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association.The Guidelineof Prevention and Treatment for Chronic Hepatitis B (2010Version) [J].Chin J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会、中华医学会感染病分会, 慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[4]Han GR, Cao MK, Zhao W, et al.A prospective and open-label study for the efficacy and safety of telbivudine in preg-nancy for the prevention of perinatal transmission of hepatitisB virus infection[J].J Hepatol, 2011, 55 (6) :1215-1221.

[5]刘克洲, 陈智.人类病毒性疾病[M].北京:人民卫生出版社, 2002:503-504.

[6]Chatterjee S, Ravishankar K, Chatterjee R, et al.Hepatits Bprevalence during pregnany[J].Indian Pediatr, 2009, 46 (11) :1005-1008.

[7]Sinha S, Kumar M.Pregnancy and chronic hepatitis B virusinfection[J].Hepatol Res, 2010, 40 (1) :31-48.

[8] Han GR, Jiang HX, Wang GJ, et al.Efficacy and safety ofteibivudine in pregnant women to prevent perinatai transmis-sion of hepatitis B virus[J].Chin J Hepatol, 2012, 20 (3) :201-205. (in Chinese) 韩国荣, 江红秀, 王根菊, 等.替比夫定乙型肝炎病毒高载量孕妇母婴传播的阻断效果及其安全性[J].中华肝脏病杂志, 2012, 20 (3) :201-205.

[9]Chen XQ, Yao ZC, Wu LP, et al.Clinical study on telbivudi-ne in preventing mother-to-infant HBV transmission dur-ing the late pregnancy[J].Chin J Clin Hepatol, 2011, 27 (12) :1282-1284. (in Chinese) 陈晓勤, 姚展成, 吴丽萍, 等.妊娠晚期应用替比夫定阻断乙型肝炎病毒垂直传播的临床观察[J].临床肝胆病杂志, 2011, 27 (12) :1282-1284.

[10]Bridges EG, Selden JR, Luo S.Nonclinical safety profile oftelbivudine, a novel potent antiviral agent for treatment ofhepatitis B[J].Antimicrob Agents Chemother, 2008, 52 (7) :2521-2528.

Relative Articles

[1]	Wang Chong, Cao MengZhuo, Wang Chuan, Jiang Jing, Li Jie, Niu JunQi. Research advances in the application of telbivudine during pregnancy to prevent HBV mother-to-child transmission[J]. Journal of Clinical Hepatology, 2017, 33(4): 746-750. doi: 10.3969/j.issn.1001-5256.2017.04.035
[2]	Zhu YunXia, Wang Ming, Chen Yu, Bian Qian, Zou HuaiBin, Zhuo XiuPing, Meng Jun, Zhang ShiBin. Clinical effect of telbivudine in treatment of pregnant women with hepatitis B virus infection and a low-level increase in alanine aminotransferase[J]. Journal of Clinical Hepatology, 2017, 33(8): 1471-1474. doi: 10.3969/j.issn.1001-5256.2017.08.011
[3]	Peng MeiJuan, Wang Wei, Yang XiaoFei, Hao ChunQiu, Bai XueFan, Jia ZhanSheng, Lian JianQi, Zhang Ye. Influence of pegylated interferonα- 2a versus telbivudine on renal function in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 682-686. doi: 10.3969/j.issn.1001-5256.2016.04.014
[4]	Huang ShuiWen, Liu BaoRong, Chen MingSheng, Lin Chun, Zhou Rui, Yang HuiAn, Jiang XiaoYan, Pan Chen, Li DongLiang. Establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B patients treated with telbivudine[J]. Journal of Clinical Hepatology, 2016, 32(7): 1287-1291. doi: 10.3969/j.issn.1001-5256.2016.07.014
[5]	Wang Fang, Quan ZuoHua, Yang XingKun, Kou JunFeng, Yun ShengHao, Cai GuoFang, Zhou XinRen. Influence of antiviral therapy with telbivudine on serum soluble complement receptor type 1 in patients with chronic hepatitis B or liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1118-1120. doi: 10.3969/j.issn.1001-5256.2016.06.019
[6]	Yu YueCheng, Hou JinLin. ACG clinical guideline(2016): liver disease and pregnancy[J]. Journal of Clinical Hepatology, 2016, 32(4): 619-627. doi: 10.3969/j.issn.1001-5256.2016.04.002
[7]	Wang RongQi, Nan YueMin. Neutropenia caused by telbivudine in chronic hepatitis B patients: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(2): 273-274. doi: 10.3969/j.issn.1001-5256.2015.02.031
[8]	Guo RuYi, Yu XuePing, Su ZhiJun, Lin ChengZu, Lin ZhiPeng, Lin Qi. Evaluation of telbivudine’s efficacy for treating HBeAg-positive chronic B hepatitis patients and identification of its predictive factors by logistic regression analysis[J]. Journal of Clinical Hepatology, 2013, 29(2): 97-100.
[9]	Dong XiaoPing. Therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in treatment of liver fibrosis in chronic hepatitis B: a report of 60 cases[J]. Journal of Clinical Hepatology, 2013, 29(9): 689-691. doi: 10.3969/j.issn.1001-5256.2013.09.014
[10]	Sun WeiHui, Chu LeiLei, Liu WeiLin, Hao AnHua, Ma Lei, Wan Qiang, Ren Rong, Xin YongNing. Efficacy and safety of telbivudine in preventing mother-to-infant transmission of HBV in pregnant women with high HBV DNA load[J]. Journal of Clinical Hepatology, 2013, 29(8): 596-599. doi: 10.3969/j.issn.1001-5256.2013.08.011
[11]	Zhang XueHua, Zhu ChuanWu, Luo XiangRong, Chai XiaoZhe. Therapeutic efficacy of telbivudine for treating chronic hepatitis B patients with elevated levels of serum soluble E-selectin[J]. Journal of Clinical Hepatology, 2012, 28(11): 839-840+844.
[12]	Xie Rong, Jiang JianNing, Su MingHua, Liu ZhiHong, Zhong ShaoHua, He LiXia, Liang YanXiu, Hu JiaGuang, Huang XiaoHong, Guo WenWen, Fu WuDao, Zhu MeiQin, Wang BaoJian. Efficacy and safety of initial telbivudine treatment in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(6): 422-424+427.
[13]	Zhao WenLi, Wang BaoChun, Huang Fei. Therapeutic effects of 48-week telbivudine treatment in patients with cirrhosis caused by HBV[J]. Journal of Clinical Hepatology, 2011, 27(8): 840-843.
[14]	Yao QinJiang, Ma WeiGuo. Therapeutic efficacy of telbivudine in hepatitis B e antigen positive chronic hepatitis B patients with high baseline alanine aminotransferase levels[J]. Journal of Clinical Hepatology, 2011, 27(6): 614-616.
[15]	Song LiWen, Zhao GuiMing, Cao WuKui, Lu ChengZhen. Meta analysis of the comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(9): 955-961.
[16]	Wang HaiYan, Wang Yu, Peng XiaoMing, Liu Ya. Recent advancement of telbivudine in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(12): 1320-1322+1326.
[17]	Zhan GuoQing, Tan HuaBing, Zhang WeiWei, Li RuGui, Xie XingRong, Hu Bo. The factors predicting the efficacy of telbivudine in the treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(6): 608-610.
[18]	Jin QingLong, Wang ZhongFeng, Yan HongQing, Niu JunQi. The study of the change in creatine kinase in patients with chronic hepatitis B during the antiviral treatment with Telbivudine and Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(2): 143-144+156.
[19]	Chen XiaoQin, Yao ZhanCheng, Wu LiPing, Chen MingChun, Zhang YanPing, Wu Yi. Clinical study on telbivudine in preventing mother-to-infant HBV transmission during the late pregnancy[J]. Journal of Clinical Hepatology, 2011, 27(12): 1282-1284.
[20]	Li Zhi, Yan HongMei, Xue FaXuan, Wang Tong, Liang Qun, Xu Huan, Li ZhangChun. Short-term clinical effect of telbivudine in the treatment chronic hepatitis B[J]. Journal of Clinical Hepatology, 2009, 25(6): 420-421+426.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3798) PDF downloads(729)

Clinical trial of telbivudine in the treatment of chronic hepatitis B in patients during the third trimester of pregnancy

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical trial of telbivudine in the treatment of chronic hepatitis B in patients during the third trimester of pregnancy

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content